prikaz prve stranice dokumenta Expert opinion on current and future prophylaxis therapies aimed at improving protection for people with hemophilia A
  Preuzmi
PDF 900.19 KB
Znanstveni rad - Izvorni znanstveni rad
Expert opinion on current and future prophylaxis therapies aimed at improving protection for people with hemophilia A
Journal of Medicine and Life, 15 (2022), 4; 570-578. https://doi.org/10.25122/jml-2022-0103
Batorova, Angelika; Boban, Ana; Brinza, Melen; Lissitchkov, Toshiko; Nemes, Laszlo; Preložnik Zupan, Irena; Smejkal, Petr; Zozulya, Nadezhda; Windyga, Jerzy

Citiranost:
,
Citirajte ovaj rad

Batorova, A., Boban, A., Brinza, M., Lissitchkov, T., Nemes, L., Preložnik Zupan, I. ... Windyga, J. (2022). Expert opinion on current and future prophylaxis therapies aimed at improving protection for people with hemophilia A. Journal of Medicine and Life, 15. (4), 570-578. doi: 10.25122/jml-2022-0103

Batorova, Angelika, et al. "Expert opinion on current and future prophylaxis therapies aimed at improving protection for people with hemophilia A." Journal of Medicine and Life, vol. 15, br. 4, 2022, str. 570-578. https://doi.org/10.25122/jml-2022-0103

Batorova, Angelika, Ana Boban, Melen Brinza, Toshiko Lissitchkov, Laszlo Nemes, Irena Preložnik Zupan, Petr Smejkal, Nadezhda Zozulya i Jerzy Windyga. "Expert opinion on current and future prophylaxis therapies aimed at improving protection for people with hemophilia A." Journal of Medicine and Life 15, br. 4 (2022): 570-578. https://doi.org/10.25122/jml-2022-0103

Batorova, A., et al. (2022) 'Expert opinion on current and future prophylaxis therapies aimed at improving protection for people with hemophilia A', Journal of Medicine and Life, 15(4), str. 570-578. doi: 10.25122/jml-2022-0103

Batorova A, Boban A, Brinza M, Lissitchkov T, Nemes L, Preložnik Zupan I, i sur.. Expert opinion on current and future prophylaxis therapies aimed at improving protection for people with hemophilia A. Journal of Medicine and Life [Internet]. 04.2022. [pristupljeno 04.04.2025.];15(4):570-578. doi: 10.25122/jml-2022-0103

A. Batorova, et al., "Expert opinion on current and future prophylaxis therapies aimed at improving protection for people with hemophilia A", Journal of Medicine and Life, vol. 15, br. 4, str. 570-578, Travanj 2022. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:105:402005. [Citirano: 04.04.2025.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:105:402005
Prijavite se u repozitorij kako biste mogli spremiti objekt u svoju listu.
Podaci o radu
Naslov (engleski)Expert opinion on current and future prophylaxis therapies aimed at improving protection for people with hemophilia A
AutorAngelika Batorova
AutorAna Boban
AutorMelen Brinza
AutorToshiko Lissitchkov
AutorLaszlo Nemes
AutorIrena Preložnik Zupan
AutorPetr Smejkal
AutorNadezhda Zozulya
AutorJerzy Windyga
Autorova ustanovaSveučilište u Zagrebu
Medicinski fakultet
(KATEDRA ZA INTERNU MEDICINU)
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Interna medicina
Sažetak (engleski)
The next frontier in hemophilia A management has arrived. However, questions remain regarding the broader applicability of new and emerging hemophilia A therapies, such as the long-term safety and efficacy of non-factor therapies and optimal regimens for individual patients. With an ever-evolving clinical landscape, it is imperative for physicians to understand how available and future hemophilia A therapies could potentially be integrated into real-life clinical practice to improve patient... Više outcomes. Against this background, nine hemophilia experts from Central European countries participated in a pre-advisory board meeting survey. The survey comprised 11 multiple-choice questions about current treatment practices and future factor and non-factor replacement therapies. The survey questions were developed to reflect current unmet needs in hemophilia management reflected in the literature. The experts also took part in a follow-up advisory board meeting to discuss the most important unmet needs for hemophilia management as well as the pre-meeting survey results. All experts highlighted the challenge of maintaining optimal trough levels with prophylaxis as their most pressing concern. Targeting trough levels of ≥30–50 IU/L or even higher to achieve less bleeding was highlighted as their preferred strategy. However, the experts had an equal opinion on how this could be achieved (i.e., more efficacious non-factor therapies or factor therapy offering broader personalization possibilities such as targeting trough levels to individual pharmacokinetic data). In summary, our study favors personalized prophylaxis to individual pharmacokinetic data rather than a "one-size-fits-all" approach to hemophilia A management to maintain optimal trough levels for individual patients. Sakrij dio sažetka
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Izvorni znanstveni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaJournal of Medicine and Life
Brojčani podacivol. 15, br. 4, str. 570-578
p-ISSN1844-122X
e-ISSN1844-3117
DOIhttps://doi.org/10.25122/jml-2022-0103
URN:NBNurn:nbn:hr:105:402005
Datum objave publikacije2022-04
URL dokumentahttps://medandlife.org/wp-content/uploads/JMedLife-15-570.pdf
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Imenovanje 4.0 međunarodna (CC BY 4.0)
Datum i vrijeme pohrane2022-12-12 09:14:20
accessibility

closePristupačnostrefresh

Ako želite spremiti trajne postavke, kliknite Spremi, ako ne - vaše će se postavke poništiti kad zatvorite preglednik.